A study to assess how much burden acute kidney injury adds to the costs in the IC
Not Applicable
- Conditions
- Health Condition 1: N178- Other acute kidney failure
- Registration Number
- CTRI/2021/08/035650
- Lead Sponsor
- KASTURBA MEDICAL COLLEGEMANIPA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patient admission to ICU with AKI and without AKI.
Patient with Stage 1,stage 2, stage 3 of AKI classification by KDIGO criteria
Patient of age group more than or 18 years old
Exclusion Criteria
All patients who have been partially treated elsewhere for the condition
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It will help to check the cost burden on acute kidney injury patients and to frame policy for acute kidney disease managementTimepoint: Baseline data in 6 weeks and outcome 6 months
- Secondary Outcome Measures
Name Time Method Reduced cost burden towards AKI for the patient with better health outcomeTimepoint: 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What biomarkers predict acute kidney injury (N178) in ICU patients and influence treatment costs?
How does acute kidney injury management in Kasturba Medical College's ICU compare economically to standard protocols?
What molecular pathways contribute to the economic burden of acute kidney injury in intensive care units?
Are there cost-effective interventions for preventing acute kidney injury in high-risk ICU populations?
What are the long-term economic implications of acute kidney injury on post-ICU recovery and healthcare systems?